Jacobs Levy Equity Management
ABOS icon

Jacobs Levy Equity Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.7K Buy
+13,011
New +$33.2K ﹤0.01% 952
2025
Q4 		– Sell
-16,001
Closed -$27.4K – 918
2025
Q3 		$27.4K Buy
+16,001
New +$22.1K ﹤0.01% 953

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Jacobs Levy Equity Management's ABOS Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2026: 13,011 shares worth $30.7K. The stake represents ﹤0.01% of the portfolio and ranks #952 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in ABOS as recently as Q3 2025.

Jacobs Levy Equity Management first reported a position in ABOS in Q3 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Jacobs Levy Equity Management held 13,011 shares of Acumen Pharmaceuticals worth $30.7K as of Q1 2026.
  • Acumen Pharmaceuticals was a new Jacobs Levy Equity Management position in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #952 holding.
  • Jacobs Levy Equity Management first reported a position in Acumen Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.